Literature DB >> 10434295

From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease.

S W Davies1, M Turmaine, B A Cozens, A S Raza, A Mahal, L Mangiarini, G P Bates.   

Abstract

Huntington's disease (HD) is an inherited progressive neurodegenerative disease caused by the expansion of a polyglutamine repeat sequence within a novel protein. Recent work has shown that abnormal intranuclear inclusions of aggregated mutant protein within neurons is a characteristic feature shared by HD and several other diseases involving glutamine repeat expansion. This suggests that in each of the these disorders the affected nerve cells degenerate as a result of these abnormal inclusions. A transgenic mouse model of HD has been generated by introducing exon 1 of the HD gene containing a highly expanded CAG sequence into the mouse germline. These mice develop widespread neuronal intranuclear inclusions and neurodegeneration specifically within those areas of the brain known to degenerate in HD. We have investigated the sequence of pathological changes that occur after the formation of nuclear inclusions and that precede neuronal cell death in these cells. Although the relation between inclusion formation and neurodegeneration has recently been questioned, a full characterization of the pathways linking protein aggregation and cell death will resolve some of these controversies and will additionally provide new targets for potential therapies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10434295      PMCID: PMC1692604          DOI: 10.1098/rstb.1999.0448

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  45 in total

1.  Alterations in dopaminergic receptors in Huntington's disease.

Authors:  T D Reisine; J Z Fields; L Z Stern; P C Johnson; E D Bird; H I Yamamura
Journal:  Life Sci       Date:  1977-10-15       Impact factor: 5.037

2.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid.

Authors:  M F Beal; N W Kowall; D W Ellison; M F Mazurek; K J Swartz; J B Martin
Journal:  Nature       Date:  1986 May 8-14       Impact factor: 49.962

3.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene.

Authors:  J H Cha; C M Kosinski; J A Kerner; S A Alsdorf; L Mangiarini; S W Davies; J B Penney; G P Bates; A B Young
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Benzodiazepine and GABA receptors in early Huntington's disease.

Authors:  F O Walker; A B Young; J B Penney; K Dovorini-Zis; I Shoulson
Journal:  Neurology       Date:  1984-09       Impact factor: 9.910

5.  [3H]mazindol binding associated with neuronal dopamine uptake sites in corpus striatum membranes.

Authors:  J A Javitch; R O Blaustein; S H Snyder
Journal:  Eur J Pharmacol       Date:  1983-06-17       Impact factor: 4.432

6.  Autoradiographic characterization of N-methyl-D-aspartate-, quisqualate- and kainate-sensitive glutamate binding sites.

Authors:  J T Greenamyre; J M Olson; J B Penney; A B Young
Journal:  J Pharmacol Exp Ther       Date:  1985-04       Impact factor: 4.030

7.  Properties of D2 dopamine receptor autoradiography: high percentage of high-affinity agonist sites and increased nucleotide sensitivity in tissue sections.

Authors:  E K Richfield; A B Young; J B Penney
Journal:  Brain Res       Date:  1986-09-24       Impact factor: 3.252

8.  Quantitative autoradiography of neurotransmitter receptors in Huntington disease.

Authors:  J B Penney; A B Young
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

9.  Neuropathological classification of Huntington's disease.

Authors:  J P Vonsattel; R H Myers; T J Stevens; R J Ferrante; E D Bird; E P Richardson
Journal:  J Neuropathol Exp Neurol       Date:  1985-11       Impact factor: 3.685

10.  gamma-Aminobutyric acid receptors in normal human brain and Huntington disease.

Authors:  P C Van Ness; A E Watkins; M O Bergman; W W Tourtellotte; R W Olsen
Journal:  Neurology       Date:  1982-01       Impact factor: 9.910

View more
  11 in total

Review 1.  Neural transplantation in patients with Huntington's disease.

Authors:  Anne E Rosser; Stephen B Dunnett
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

3.  Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.

Authors:  Ivan Tkac; Janet M Dubinsky; C Dirk Keene; Rolf Gruetter; Walter C Low
Journal:  J Neurochem       Date:  2007-01-08       Impact factor: 5.372

4.  Motor function and dopamine release measurements in transgenic Huntington's disease model rats.

Authors:  Andrea N Ortiz; Gregory L Osterhaus; Kelli Lauderdale; Luke Mahoney; Stephen C Fowler; Stephan von Hörsten; Olaf Riess; Michael A Johnson
Journal:  Brain Res       Date:  2012-02-24       Impact factor: 3.252

Review 5.  The early cellular pathology of Huntington's disease.

Authors:  X J Li
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

6.  Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.

Authors:  K P Murphy; R J Carter; L A Lione; L Mangiarini; A Mahal; G P Bates; S B Dunnett; A J Morton
Journal:  J Neurosci       Date:  2000-07-01       Impact factor: 6.167

7.  Cardiac dysfunction in the R6/2 mouse model of Huntington's disease.

Authors:  Michael J Mihm; Deborah M Amann; Brandon L Schanbacher; Ruth A Altschuld; John Anthony Bauer; Kari R Hoyt
Journal:  Neurobiol Dis       Date:  2006-11-27       Impact factor: 5.996

8.  Deletion of the huntingtin polyglutamine stretch enhances neuronal autophagy and longevity in mice.

Authors:  Shuqiu Zheng; Erin B D Clabough; Sovan Sarkar; Marie Futter; David C Rubinsztein; Scott O Zeitlin
Journal:  PLoS Genet       Date:  2010-02-05       Impact factor: 5.917

9.  A series of N-terminal epitope tagged Hdh knock-in alleles expressing normal and mutant huntingtin: their application to understanding the effect of increasing the length of normal Huntingtin's polyglutamine stretch on CAG140 mouse model pathogenesis.

Authors:  Shuqiu Zheng; Nima Ghitani; Jessica S Blackburn; Jeh-Ping Liu; Scott O Zeitlin
Journal:  Mol Brain       Date:  2012-08-14       Impact factor: 4.041

10.  Generation and Characterization of Knock-in Mouse Models Expressing Versions of Huntingtin with Either an N17 or a Combined PolyQ and Proline-Rich Region Deletion.

Authors:  Emily A André; Elise M Braatz; Jeh-Ping Liu; Scott O Zeitlin
Journal:  J Huntingtons Dis       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.